A Five-year Commitment From Takeda Will Help Children’s National Launch a First-of-its-Kind Rare Disease Clinical Protocol Program
WASHINGTON, DC and CAMBRIDGE, MA, March 1, 2021 — Children’s National Hospital and Takeda Pharmaceutical Company Limited (“Takeda”) announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.
Rare-CAP will be led by the Rare Disease Institute at the new Children’s National Research & Innovation Campus that opened in February 2021 on the grounds of the former Walter Reed Army Medical Center. Read the full press release.
